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1  | INTRODUC TION
Despite advancements in medical and surgical management, heart 
transplantation is the only life-prolonging option for some pediatric 
patients with end-stage heart disease. According to data from the 
Pediatric Heart Transplant Study, the numbers of both listed and 
transplanted pediatric patients are slowly increasing, with improving 
post-transplant survival.1 However, the risk of morbidity and death 
remain. For many pediatric patients and their caregivers, life post–
heart transplantation results in improved physical functioning, but 
also involves the management of a new chronic condition and the 
potential for complications such as infection, rejection, renal failure, 
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Abstract
Mental health concerns are associated with worse outcomes after adult heart trans-
plant. Illness-specific anxiety is associated with worsened psychological well-being 
after other solid organ transplants but has never been characterized after pediatric 
heart transplant. This single-center cross-sectional study aimed to evaluate illness-
specific and generalized anxiety after heart transplantation in adolescents. A novel 
12-item PHTF, GAD-7, and the PedsQL were administered. Univariate associations 
of demographics, clinical features, and medication adherence as measured by immu-
nosuppression standard deviation with the PHTF and GAD-7 scores were evaluated. 
Internal consistency and validity of the PHTF were examined. In total, 30 patients 
participated. The most common illness-specific fears were retransplantation, rejec-
tion, and more generally post-transplant complications. The PHTF had good internal 
consistency (Cronbach α = .88). Construct validity was demonstrated between PHTF 
and GAD-7 (r = .62) and PedsQL (r	=	−.54	to	−.62).	23%	endorsed	moderate	to	severe	
generalized anxiety symptoms. More severe symptoms were associated with older 
age at survey (P = .03), older age at listing (P = .01) and having post-transplant com-
plications (P = .004). Patients with moderate or severe symptoms were more likely 
to report late immunosuppression doses (P = .004). Illness-specific and generalized 
anxiety may be prevalent after pediatric heart transplant. Screening for anxiety in ad-
olescents post-transplant may identify those at risk for adverse outcomes including 
non-adherence. The PHTF is a brief, valid, and reliable instrument identifying illness-
specific anxiety in this population.
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and malignancy.1 In addition, transplant recipients face the inevi-
table risk of coronary allograft vasculopathy which increases with 
time,2 resulting ultimately in reoccurrence of heart failure symptoms 
and potential for retransplantation.
Transplantation also seeks to improve the health-related quality 
of life for pediatric patients with end-stage heart disease; however, a 
subset remains at risk for impaired psychological well-being following 
transplant,3 as well as impaired health-related quality of life, neuropsy-
chological outcomes, and family function as compared to non-trans-
plant recipients.4 While mental health disorders are well studied in 
adult patients after heart transplantation,5-7 less is known about the 
long-term mental health of pediatric heart transplant recipients.8-10
Limited studies suggest that pediatric heart transplant patients 
may have increased risk of psychological disorders when compared 
to the general population. One study found that a quarter or greater 
of pediatric heart transplant recipients are at risk for emotional 
adjustment issues immediately following transplant.11 Previous re-
search suggests that approximately a third of patients continue to 
experience significant psychosocial distress in the years following 
heart transplantation,12 including symptoms of post-traumatic stress 
disorder 13 and emotional and behavioral disorders.14 It is possible 
that mental health concerns are worse in patients with a more com-
plicated clinical course, given prior studies in adult heart transplant 
patients associating anxiety and depression and hospital length of 
stay,7 although this association has not been explored in the pedi-
atric population.
The causes of impaired psychological well-being after heart 
transplant are not well understood. It is possible that illness-specific 
anxiety about post-transplant complications contributes to worse 
health-related quality of life post-transplant. Fear of rejection fol-
lowing solid organ transplants has been identified in an adult pop-
ulation,15,16 and intrusive thoughts about graft rejection have been 
shown to contribute to poor psychological well-being after lung 
transplantation.17 Across other chronic illness populations, there is 
growing evidence for the presence of illness-specific anxiety and 
fears related to disease progression or recurrence,18-20 distinct 
from generalized anxiety disorder.21 Importantly, illness-specific 
anxiety has been associated with generalized anxiety, depression, 
and increased healthcare utilization in other adult chronic illness 
populations.22
In adult transplant patients, mental health concerns such as 
generalized anxiety and depression are also associated with in-
creased risk of graft loss and death.23 One factor contributing to 
poor outcomes in adult recipients may be the association between 
poor mental health and non-adherence to medication regimen.24,25 
Mental health concerns in pediatric transplant patients may similarly 
contribute to non-adherence, which in turn increases morbidity and 
mortality.26 Illness-specific anxiety as a possible contributor has yet 
to be studied in pediatric transplant recipients. Adult transplant and 
other chronic illness literatures underscore the importance of ex-
amining illness-specific anxiety in pediatric transplant recipients as 
it may contribute to poorer mental health and subsequent risk of 
adverse health outcomes.
The aims of the current study were (a) to develop and validate a 
novel measure to assess illness-specific anxiety in adolescents after 
heart transplantation, (b) to characterize the prevalence and scope 
of illness-specific anxiety and generalized anxiety in adolescents 
after heart transplant, and (c) to evaluate for association between 
illness-specific anxiety and generalized anxiety symptoms following 
heart transplant with health experiences prior to and after transplan-
tation. It was hypothesized that illness-specific and generalized anxiety 
are both prevalent among adolescent patients post–heart transplanta-
tion. It was also hypothesized that illness-specific and generalized anx-
iety are associated with complications in clinical course both before 
and after transplantation and worse medication adherence.
2  | METHODS
2.1 | Procedures and recruitment
This single-center cross-sectional study included all patients with 
a history of heart transplantation greater than 12 years of age fol-
lowed within a pediatric heart transplant program who gave written 
informed consent or written informed assent with parent or guardian 
written informed consent if <18 years of age. Patients were excluded 
if they were non-English speaking or unable to complete the ques-
tionnaires due to cognitive/developmental impairment. Two patients 
were excluded as they were assessed to be nearing end of life by the 
clinical team, and thus likely to be inappropriate for the present study.
The study was approved by the Institutional Review Board. Heart 
transplant recipients were approached by the principal investigator or 
the research coordinator at the time of a routine outpatient follow-up 
visit and enrolled patients independently completed all measures de-
tailed below. Demographic characteristics and information on clinical 
course were obtained by review of the electronic health record.
2.2 | Adherence
Immunosuppression troughs were recorded, and a standard devia-
tion of trough levels was calculated as a surrogate for medication 
adherence.27,28 Additionally, patients' self-report of adherence 
was obtained by review of clinic notes on the day of the surveys. 
Specifically, patients were asked “how many missed or late immuno-
suppression doses have you had in the last week?”.
2.3 | Existing measures
The GAD-7 is a self-report instrument designed for adults consisting of 
seven items measuring generalized anxiety. Items have four response 
options increasing in frequency, and scores are summed with higher 
scores reflecting higher severity of symptoms.29 The GAD-7 has been 
validated for detection of anxiety symptoms in adolescents with gen-
eralized anxiety disorder30 and adult heart transplant recipients.31
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The PedsQL 4.0 Generic Core Scale is a 23-item instrument that 
assesses physical, emotional, social, and school functioning. The 
PedsQL 3.0 Cardiac Module is a 27-item instrument that assesses 
symptom burdens, perceived physical appearance, treatment anxi-
ety, cognitive problems, and communication. All items are scored on 
a	5-point	Likert	scale.	 Items	are	 reverse-scored	and	 linearly	 trans-
formed to a 100-point scale such that higher scores indicate a better 
health-related quality of life. The PedsQL Generic Core Scale is used 
to create a psychosocial health summary score, computed as the sum 
of the items divided by the number of items in the emotional, social, 
and school functioning scales.32 Both the PedsQL 4.0 Generic Core 
Scales and PedsQL 3.0 Cardiac Module have been utilized in pediat-
ric heart transplant recipients.3
2.4 | Statistical analyses
Data are reported as means ± standard deviations or median with 
interquartile range (IQR) for continuous variables and frequencies 
with percentages for categorical variables. Total GAD-7 scores 
were considered as both continuous and binary variables with pa-
tients dichotomized into two groups, those reporting moderate or 
severe	anxiety	symptoms	(GAD-7	score	≥10)	and	those	reporting	
minimal or mild anxiety symptoms (GAD-7 score 0-9). Associations 
of patient demographics, pretransplant course, transplant charac-
teristics, and post-transplant course with GAD-7 scores (both con-
tinuous and binary variables) were assessed using Fisher's exact 
test, Spearman correlation coefficient, Wilcoxon rank sum test, or 
Kruskal-Wallis test, as appropriate. Total (PHTF, see below) scores 
and	individual	PHTF	item	score	were	examined	as	a	5-point	Likert	
scale, as well as linearly transformed a 100-point scale such that 
higher scores indicating more anxiety. Associations between PHTF 
scores and patient demographics, pretransplant course, transplant 
characteristics, and post-transplant course were assessed using a 
two-sample t test or analysis of variance for categorical variables, 
and Spearman correlation coefficient for continuous variables. All 
analyses were performed using SAS Version 9.4 (SAS Institute Inc), 
with statistical significance set at a P-value	<.05	using	a	two-sided	
test.
3  | PHTF: ME A SURE DE VELOPMENT AND 
VALIDATION
3.1 | Measure development
The novel PHTF questionnaire was developed after discussion 
with an experienced survey researcher. Validated measures of 
illness-specific anxiety in other chronic disease states were re-
viewed.16-20,33 Items from published measures that were applicable 
to the post–heart transplant experience were selected or adapted 
as appropriate, and nine items were selected with responses on 
a	5-point	Likert	scale	ranging	from	“never”	(1)	to	“always”	(5).	An	
additional three items were included inquiring about understand-
ing of complications of heart transplantation and discussing wor-
ries about complications with loved ones and healthcare team 
members	with	 responses	 on	 a	 5-point	 Likert	 scale	 ranging	 from	
“strongly	disagree”	(1)	to	“strongly	agree”	(5).	All	metric	items	were	
discussed with experts in medical management of pediatric heart 
transplantation as well as psychological care post pediatric heart 
transplantation. The PHTF was reviewed by two adolescent heart 
transplant patients for comprehension and context prior to con-
ducting the study. The PHTF questionnaire items are included in 
Table 3.
3.2 | Psychometric properties of PHTF
The psychometric properties of the PHTF were examined. Scale 
internal consistency reliability was determined by Cronbach's coef-
ficient alpha (α). To establish construct validity, intercorrelations be-
tween the PHTF scores and total GAD-7 score, PedsQL 4.0 Generic 
Core Scale Psychosocial summary score, and PedsQL Cardiac 
Module Treatment Anxiety subscale score were performed using 
Pearson or Spearman correlation coefficient.
The internal consistency of the PHTF was good (Cronbach 
α = .88). Construct validity was also demonstrated with medium to 
high r values between PHTF total score, GAD-7 total score (r = .62) 
and the PedsQL Psychosocial summary score (r	=	−.54)	and	Cardiac	
Module Treatment Anxiety subscale score (r	=	−.62;	Table	1).
4  | RESULTS
4.1 | Patient characteristics
Table 2 summarizes patient demographic and clinical characteris-
tics. Of 31 eligible patients, only one patient declined participation 
in	 the	 study	 yielding	 a	 participation	 rate	 of	 97%.	Most	 patients	
were	 male	 (73.3%)	 and	 Caucasian	 (80%)	 with	 a	 median	 age	 of	
17.5	 years.	 There	 was	 about	 equal	 representation	 of	 pretrans-
plant diagnosis of congenital heart disease and cardiomyopathy. 
Median time from transplant at the time of survey was 8.0 years. 
Thirty percent of patients had experienced a pretransplant com-
plication including cardiac arrest, stroke, need for (ECMO) and/
or need for (VAD). Thirty percent of patients experienced a post-
transplant clinical complication including cardiac arrest, stroke, 




Most	 patients	were	 on	 tacrolimus	 (93.3%)	with	 a	median	 immuno-
suppression	standard	deviation	of	1.56	(43%	≥2).	Twenty	percent	of	
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patients reported at least one late dose of immunosuppression in the 
last week.
4.3 | Illness-specific anxiety
There was a significant association between greater PHTF score 
and greater GAD-7 score or more severe generalized anxi-
ety (r = .62, P = .0003). There also was a significant association 
between greater PHTF score with a lower PedsQL total score 
(r	 =	 −.56,	 P = .001) and PedsQL Psychosocial subscale score 
(r	=	−.54,	P = .002), indicating worse health-related quality of life 
and psychological well-being.
There were three items within the PHTF that a notable percent-
age of patients reported worrying about “often” or “always” (Table 3). 
These included worrying about rejection while waiting for biopsy 
results	 (26.7%),	worrying	 about	needing	 another	 transplant	 (20%),	
and	serious	post-transplant	complications	(20%).	When	specifically	
asked about their worries, a notable percentage of patients reported 
that they were not discussing fears about long-term complications 
with their family or providers. About a quarter of patients chose 
that they “disagree” or “strongly disagree” with the statement that 
they discuss their worries about long-term complications of heart 
transplantation	with	their	 loved	ones	 (23.3%)	and	healthcare	team	
(13.3%),	and	10%	disagreed	that	they	had	a	good	understanding	of	
the complications of heart transplant.
Higher overall illness-specific anxiety was associated with 
female gender (mean PHTF score 46.2 ± 14.0 vs 23.8 ± 22.7 in 
male, P = .01). Individual PHTF item analysis revealed a significant 
association	 between	 immunosuppression	 standard	 deviation	 ≥2	
and increased patient worry about rejection while waiting for 
TA B L E  1   PHTF validation: correlation between overall anxiety 
score from PHTF questionnaires and other validated measures 
(GAD-7, PedsQL)
 r P
GAD-7 total score 0.62 .0003
PedsQL generic core total score −0.56 .001
Physical functioning subscale −0.48 .01
Psychosocial Summary subscale −0.54 .002
Emotional functioning subscale −0.71 <.0001
Social functioning subscale −0.32 .09
School functioning subscale −0.18 .36
PedsQL cardiac module
Heart problems and treatment subscale −0.44 .02
Treatment II subscale (if taking 
medications)
−0.49 .01
Perceived physical appearance subscale −0.71 <.0001
Treatment anxiety subscale −0.62 .0003
Cognitive problems subscale −0.28 .13
Communication subscale −0.67 <.0001
Data are presented as r, Pearson or Spearman correlation coefficient 
(P-value).
TA B L E  2   Patient demographic, transplant, and post-transplant 
characteristics	(N	=	30)
 




Male gender 22 (73.3)
Age at survey, years 17.5	(15.6-19.2)
Time from transplant to survey, years 8.0 (4.0-14.6)
Caucasian race 24 (80.0)
Diagnosis
Cardiomyopathy 15	(50.0)
Congenital heart disease 14 (46.7)
Other (Familial hyperlipidemia) 1 (3.3)
Pretransplant 9 (30.0)
History of cardiac arrest 3 (10.0)
History of stroke 1 (3.3)
Need	for	ECMO 5	(16.7)
Need	for	VAD 2 (6.7)















Hospital length of stay since Transplant, days 
(N	=	29)
14 (12-22)
Post-transplant complication 9 (30.0)




Coronary vasculopathy 9 (30.0)
Post-transplant lymphoproliferative disorder 
(PTLD)
4 (13.3)
Antibody mediated rejection (AMR) 3 (10.0)
Rejection episodes 10 (33.3)
Unplanned hospitalization in the past year 7 (23.3)
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biopsy	results	(mean	61.5	±	32.1	vs	41.7	±	25.7	SD	<	2,	P = .04). 
There were no other associations of demographic or clinical 
features with PHTF total score, including age at survey (r = .28, 
P = .13) and post-transplant complications including cardiac arrest, 
stroke, ECMO, or dialysis (mean 38.6 ± 21.6 vs 24.8 ± 22.7 without 




items in the GAD-7, patients were most likely to report “becoming 
annoyed	or	 irritable”	 (43.3%),	 “feeling	afraid	as	 if	 something	awful	
might	happen”	(30%),	“feeling	nervous,	anxious,	or	on	edge”	(26.7%),	
and	“worrying	too	much	about	different	things”	(26.7%)	over	half	the	
days or nearly every day.
Higher GAD-7 scores or more severe generalized anxiety symp-
toms were significantly associated with older age at the time of the 
survey (r = .41, P = .03), older age at transplant listing (r = .46, P = .01), 
and any post-transplant complication (cardiac arrest, stroke, need for 
ECMO	and/or	need	for	dialysis)	(median	GAD-7	score	10	vs	1.5	with-
out complication, P = .004). Each post-transplant complication was 
evaluated	 individually,	and	both	stroke	 (median	15	vs	3.5,	P = .03) 
and	need	 for	ECMO	(median	10	vs	2.5,	P = .01) were significantly 
associated with more severe generalized anxiety symptoms. There 
were no significant associations with any other patient demographic 
criteria, pretransplant complications, history of rejection, history of 
coronary vasculopathy, ED visits or hospitalizations, or immunosup-
pression trough standard deviation.
Notably,	 moderate	 or	 severe	 generalized	 anxiety	 symptoms	
were significantly associated with patients reporting late (>2 hours 
after dose time) or missed immunosuppression doses within the past 
2	weeks	(57.1%	vs.	8.7%,	P = .004) during clinical interview, compared 
to those that expressed minimal or mild generalized anxiety symptoms.
5  | DISCUSSION
To our knowledge, this is the first study to evaluate illness-specific 
anxiety in pediatric patients after heart transplantation. In addi-
tion, the study may provide further insight into the prevalence 
TA B L E  3  PHTF	questionnaires	N	=	30
 Never Rarely Sometimes Often Always Not reported
How often do the following statements apply to you
I worry about needing another transplant 8 (26.7) 7 (23.3) 9 (30.0) 2 (6.7) 4 (13.3) –
I am nervous prior to doctor's appointments 15	(50.0) 7 (23.3) 4 (13.3) 2 (6.7) 2 (6.7) –
I worry about rejection of my heart waiting 
for results from my biopsies
9 (30.0) 7 (23.3) 6 (20.0) 4 (13.3) 4 (13.3) –
I worry about rejection of my heart waiting 
for results of my blood work
10 (33.3) 7 (23.3) 5	(16.7) 3 (10.0) 5	(16.7) –
I worry about missing school or work due to 
complications of my heart transplant
14 (46.7) 7 (23.3) 3 (10.0) 5	(16.7) 0 (0.0) 1 (3.3)
I worry about serious post-transplant 
complications
10 (33.3) 9 (30.0) 5	(16.7) 3 (10.0) 3 (10.0) –
I worry that if I develop complications from 
my heart transplant, it may hurt my friend-
ships and relationships
15	(50.0) 4 (13.3) 7 (23.3) 3 (10.0) 1 (3.3) –
When I take my medications, I think about 
rejection of my transplanted heart
13 (43.3) 8 (26.7) 6 (20.0) 1 (3.3) 2 (6.7) –
I don't enjoy life because I am worried about 
complications from my heart transplant
18 (60.0) 4 (13.3) 7 (23.3) 0 (0.0) 1 (3.3) –
 Strongly disagree Disagree Neutral Agree Strongly agree  
How much do you agree with the following statements
I have a good understanding of the long-term complica-
tions of heart transplantation
0 (0.0) 3 (10.0) 7 (23.3) 7 (23.3) 13 (43.3) –
I discuss my worries about long-term complications of 
heart transplantation with my loved ones
5	(16.7) 2 (6.7) 6 (20.0) 8 (26.7) 9 (30.0) –
I discuss my worries about long-term complications of 
my heart transplantation with my doctors and health-
care team
1 (3.3) 3 (10.0) 9 (30.0) 10 (33.3) 7 (23.3) –
Data	are	presented	as	N	(%).
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of generalized anxiety in this population. Our results suggest 
that illness-specific anxiety, as well as generalized anxiety, may 
be prevalent in adolescent and young adult patients after heart 
transplant.
Nearly	a	quarter	of	patients	in	the	study	reported	moderate	to	
severe generalized anxiety symptoms, which is almost five times 
the prevalence of generalized anxiety in the healthy adolescent 
population.34 Chronic illness in adolescents is a risk factor for anx-
iety disorders 35 which may explain the higher prevalence in the 
post-transplant population. Additionally, older patient age at the 
time of study and at listing was associated with more severe gen-
eralized anxiety symptoms. As such, it may be important to target 
this older population of pediatric heart transplant recipients for 
screening, as they may be more likely to require additional mental 
health intervention. Interestingly, generalized anxiety symptoms 
were not significantly associated with patient gender in the current 
study, whereas generalized anxiety is more prevalent in females in 
the general population.36 It may be that adolescent patients after 
heart transplant are disproportionately affected by generalized anx-
iety symptoms, regardless of gender effects. Alternatively, gender 
effects	may	not	have	been	observed	due	to	the	study's	73%	male	
predominance.
In addition to generalized anxiety, illness-specific anxiety was 
prevalent	among	the	study	sample	across	all	ages	with	20%-30%	of	
patients endorsing fears related to need for retransplantation, graft 
rejection, or complications. Furthermore, unlike with generalized 
anxiety, illness-specific anxiety was associated with female gender, 
which may identify female patients as a population at increased 
need	 for	 screening.	Notably,	 illness-specific	 anxiety	was	not	asso-
ciated with any pre– or post–heart transplant complications. Thus, 
it would seem that a notable percentage of adolescents with heart 
transplants will have worries about complications regardless of their 
clinical course. Finally, results suggested that adolescents may not 
be discussing their fears with their families or their loved ones, fur-
ther underscoring the importance of screening.
Findings also suggested that the presence of generalized anx-
iety symptoms is associated with late immunosuppression doses 
per patient report during clinical interview. This is consistent with 
previous studies that have shown that mental health disorders are 
associated with non-adherence in the adolescent population.26 
Similarly, a study of adolescent liver transplant recipients found 
that patients with greater immunosuppression standard deviation 
reported worse mental health than those with less variation of im-
munosuppressant trough levels.37 Additionally, patients in the cur-
rent study who had more variability in their immunosuppression 
trough levels were more likely to endorse illness-specific worries 
about graft rejection. Another study in adolescent transplant pa-
tients associated non-adherence with both symptoms of depression 
and worries related to their illness.38 Whether having anxiety drives 
non-adherence or non-adherence contributes to further anxiety is 
currently unclear, however, it is fair to conclude that adolescent 
patients identified with generalized or illness-specific anxiety may 
require more support to ensure medication adherence and improve 
their long-term health outcomes.
TA B L E  4  GAD-7	Scale	(N	=	30)
  Not at all sure Several days
Over half the 
days Nearly every day
Over the last 2 wk, how often have you been bothered by the following problems
Feeling nervous, anxious, or on edge  17	(56.7) 5	(16.7) 3 (10.0) 5	(16.7)
Not	being	able	to	stop	or	control	worrying  20 (66.7) 4 (13.3) 3 (10.0) 3 (10.0)
Worrying too much about different things  15	(50.0) 7 (23.3) 2 (6.7) 6 (20.0)
Trouble relaxing  18 (60.0) 8 (26.7) 2 (6.7) 2 (6.7)
Being so restless that it's hard to sit still  19 (63.3) 6 (20.0) 3 (10.0) 2 (6.7)
Becoming easily annoyed or irritable  12 (40.0) 5	(16.7) 6 (20.0) 7 (23.3)
Feeling afraid as if something awful might happen  15	(50.0) 6 (20.0) 4 (13.3) 5	(16.7)
Total score, median (IQR) 5	(0-9)	   
Minimal (score 0-4) 15	(50.0)   
Mild	(score	5-9) 8 (26.7)   
Moderate (score 10-14) 4 (13.3)   
Severe	(score	15	and	higher) 3 (10.0)   
  Not difficult at all Somewhat difficult Very difficult Extremely difficult
If you checked off any problems, how 
difficult have these made it for you to 
do your work, take care of things at 
home, or get along with other people
N	=	20 3/20	(15.0) 14/20 (70.0) 2/20 (10.0) 0/20 (0.0)
Data	are	presented	as	N	(%)	unless	otherwise	indicated.
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Like many pediatric transplant studies, this single-center sample 
size is small. The study population also only focused on adolescent 
aged pediatric transplant patients. Development of more simplistic 
metrics of illness-specific anxiety will be needed for studies with 
younger patients. Larger, multi-center studies would also be valu-
able for evaluating the prevalence of anxiety across the entire pe-
diatric heart transplant population as well as examining associations 
with longitudinal health outcomes including morbidity and mortal-
ity. Additionally, the PHTF is a novel measure, and not validated for 
transplant-specific anxiety outside of this study. The current study 
did not evaluate the presence of other mental health disorders, such 
as depression. Although anxiety and depression often overlap, prev-
alence and impact on outcomes may differ. The current study was 
also limited by the lack of reliable strategies for evaluating non-ad-
herence. While immunosuppression standard deviation has been 
used in prior studies, this is a surrogate measure of adherence which 
may be impacted by additional factors such as drug absorption or 
medication interactions.27,28 Furthermore, self-reported medication 
adherence may not always be reliable, especially in the adolescent 
population.
Despite these limitations, this study suggests that adolescent 
heart transplant patients are likely to benefit from screening for ill-
ness-specific and generalized anxiety symptoms with brief, validated 
instruments. Identification of patients with illness-specific anxiety 
and generalized anxiety may identify those at risk for medication 
non-adherence and adverse health outcomes. While there are no 
formal recommendations for psychosocial care in the pediatric heart 
transplant population, the 2010 International Society for Heart and 
Lung Transplantation Guidelines for care of heart transplant recipi-
ents recommend that each heart transplant team have a psychologist 
and that patients be regularly screened for depression.39 Many pe-
diatric centers do not have psychological support readily available,12 
particularly in outpatient clinic settings. The GAD-7 and PHTF are 
short and easy to use tools which can be used by multidisciplinary 
healthcare providers to screen and to identify transplant recipients 
in need of evaluation and formal psychological treatment.
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